Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Wells Fargo Securities Healthcare Conference 2018
12 slides from Angiodynamics's conference presentation, Sep 6, 2018
Slide 1: Wells Fargo Securities Healthcare Conference September 6, 2018
Wells Fargo Securities Healthcare Conference September 6, 2018
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash fl
Slide 3: Growth through Focus, Execution, Accountability
Growth through Focus Execution Accountablity ® angiodynamics
Slide 4: AngioDynamics Today
AngioDynamics Today 3 Focus on serving undertreated patient populations, improving patient outcomes and offering economic value to healthcare providers Operating franchises in growing, strategic markets Growth strategy to optimize product portfolio, focus on operational efficiencies and expand inter
Slide 5: Three Global Business Units with Unique Growth Opportunities
Three Global Business Units with Unique Growth Opportunities CategoriesFluid ManagementVenous InsufficiencyThrombus ManagementDrainageAngiographic CathetersKey Growth Drivers Vascular Interventions and Therapies Vascular Access Oncology CategoriesPICCsPortsDialysisKey Growth Drivers CategoriesNon-Th
Slide 6: Providing a continuum of care
Providing a continuum of care Unique, commercialized product (U.S., 2013) immediately enhances Oncology business.Adds clinically proven product to portfolio that minimizes occurrence of pneumothorax or PTX; the most common complication of CT-guided percutaneous lung biopsyProprietary hydrogel plug t
Slide 7: 2018 Scorecard: Driving transformation
2018 Scorecard Driving transformation Gross Margin Expansion Strategic Capital Allocation Simplified Footprint Portfolio Optimization Commercial Discipline
Slide 8: 2019 Framework for Growth
2019 Framework for Growth Operational Excellence Delivering sustainable and improved marginsFocused investments on growth and innovationCommitment to quality and complianceStrong cash flow generation Value Creation Practice dispassionate portfolio optimization Focus on areas of compelling unmet need
Slide 9: Financial Update
Financial Update >) angiodynamics
Slide 10: Revised FY2019 Guidance
Revised FY2019 Guidance RevenueAdjusted EPS Free Cash Flow* Previous Guidance$344-$349m$0.82-$0.86$38m - $43m Revised Guidance$348-$353m$0.82-$0.86$38m-$43m * Original and current guidance excludes the cash payment related to the DOJ legal matters disclosed previously, which was paid in 1Q FY’2019;
Slide 11: Significant Liquidity Drives Capital Allocation Strategy
Significant Liquidity Drives Capital Allocation Strategy Uses of Cash Priorities Invest internallyOpportunistically evaluate M&AExecute share buyback program authorized up to $25 million Significant cash generation and available debt capital support range of allocation options to capitalize on growt
Slide 12: Our Vision for AngioDynamics
Our Vision for AngioDynamics 3 1 2 Increase our value to each of our stakeholders Partner with providers and caregivers to deliver superior care to patients Be recognized as a consistent, high-performing MedTech company
AngioDynamics — Wells Fargo Securities Healthcare Conference 2018 on 6ix